| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IHRIC TFA does not target a specific biological receptor or enzyme. Instead, its primary target is hairpin DNA (hpDNA) with tetramer loops. The peptide exhibits improved selectivity for hpDNA structures compared to linear or single-stranded DNA, making it useful as a molecular recognition element in biosensors.
|
|---|---|
| ln Vitro |
In surface plasmon resonance (SPR) experiments, IHRIC TFA demonstrates specific and improved selectivity for hpDNA over other DNA conformations. The peptide-hpDNA interaction is characterized by a measurable binding affinity (Kd). No enzymatic activity is involved; the interaction is based on electrostatic and hydrogen bonding interactions between the positively charged peptide residues and the DNA backbone.
|
| ln Vivo |
IHRIC TFA is used in cell-free SPRi-based detection systems rather than in live-cell assays. The peptide is immobilized on a sensor chip surface, and hpDNA is flowed over the surface. The change in refractive index is measured to determine binding events. The peptide-hpDNA pair serves as a sensing platform for detecting volatile organic compounds (VOCs) or other analytes in environmental or clinical samples.
|
| Enzyme Assay |
Binding between IHRIC TFA and hpDNA is characterized using surface plasmon resonance imaging (SPRi). The penta-peptide is immobilized on the gold-coated SPRi sensor chip via amine coupling or biotin-streptavidin interaction. Varying concentrations of hpDNA (0.1-10 microM) are injected over the chip surface, and the binding response (resonance units) is recorded. The dissociation constant (Kd) is calculated from the steady-state binding curves using a 1:1 Langmuir binding model.
|
| Cell Assay |
A standard SPRi sensor chip is first cleaned and functionalized with IHRIC TFA. hpDNA samples prepared in running buffer (e.g., PBS, pH 7.4, with 1 mM MgCl2) are injected at a flow rate of 30 microL/min. Binding responses are recorded in real-time. After each cycle, the chip surface is regenerated with a mild acidic solution (e.g., 10 mM glycine-HCl, pH 2.0). Each concentration is analyzed in duplicate to ensure reproducibility.
|
| Animal Protocol |
IHRIC TFA is not used in conventional animal studies, as its primary application is in ex vivo sensor platforms. The peptide can be incorporated into implantable sensor devices for in vivo monitoring applications, but such studies would require surgical implantation of the functionalized sensor. In such setups, the peptide-hpDNA sensing layer could be evaluated in animal models under anesthesia.
|
| ADME/Pharmacokinetics |
IHRIC TFA is a synthetic peptide with a molecular weight of 754.82 Da. Its stability in biological fluids is limited due to protease degradation; however, the TFA salt form improves solubility and storage stability. For SPRi applications, the peptide is typically used in buffered aqueous solutions at neutral pH. The compound should be stored in a sealed container under nitrogen, away from moisture and light, at -20degC for long-term storage or -80degC in solution.
|
| Toxicity/Toxicokinetics |
IHRIC TFA is used only in small quantities for research purposes and has no reported acute or chronic toxicity. The TFA counterion (trifluoroacetate) is present in low, non-toxic amounts. Standard laboratory safety practices (wearing gloves, lab coat, safety glasses) should be followed when handling the compound. No specific target-related toxicity is expected because the peptide targets DNA structures rather than cellular proteins.
|
| References | |
| Additional Infomation |
IHRIC TFA is a research-use-only peptide with no clinical or therapeutic applications. It has not been approved by any regulatory authority. The penta-peptide has potential applications in the development of optoelectronic noses and VOC detection systems based on SPRi. The combination of peptide and hairpin DNA as sensing materials offers improved selectivity for biosensing platforms. The peptide sequence may be modified for specialized detection needs.
|
| Molecular Formula |
C29H49F3N10O8S
|
|---|---|
| Molecular Weight |
754.82
|
| Related CAS # |
IHRIC;2439064-86-3
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3248 mL | 6.6241 mL | 13.2482 mL | |
| 5 mM | 0.2650 mL | 1.3248 mL | 2.6496 mL | |
| 10 mM | 0.1325 mL | 0.6624 mL | 1.3248 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
